Your browser doesn't support javascript.
loading
Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening.
Ben-Shatach, Zohar; Ziv-Baran, Tomer; Fudim, Ella; Yavzori, Miri; Picard, Orit; Levartovsky, Asaf; Selinger, Limor; Weiss, Batia; Kopylov, Uri; Eliakim, Rami; Ungar, Bella.
Afiliação
  • Ben-Shatach Z; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, 52621, Israel. Sackler School of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel.
  • Ziv-Baran T; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Fudim E; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Yavzori M; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Picard O; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Levartovsky A; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Selinger L; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Weiss B; Department of Pediatric Gastroenterology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Kopylov U; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Eliakim R; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Ungar B; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Therap Adv Gastroenterol ; 15: 17562848221083395, 2022.
Article em En | MEDLINE | ID: mdl-35646158
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Risk_factors_studies Idioma: En Revista: Therap Adv Gastroenterol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Risk_factors_studies Idioma: En Revista: Therap Adv Gastroenterol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel